FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953961312> ?p ?o ?g. }

• W2953961312 abstract "Cyclin-dependent kinase 8 inhibitors (CDK8i) have anti-cancer activity in human acute myeloid leukaemia (AML) cell lines both in vitro and in vivo. Activity of CDK8i often involves deregulation of super-enhancer-associated genes in AML cell lines. Previous studies established SEL120 as a specific CDK8 inhibitor active in AML cells with increased STAT1/5 signalling pathways. Differential gene expression analysis demonstrated high enrichment of leukaemia stem cell (LSC) signatures in responding cells, linked to resistance to standard therapies and relapsed disease. Cells sensitive to SEL120 treatment were positive for CD34 and negative for lineage commitment surface markers. SEL120 markedly reduced STAT5 phosphorylation on serine 726 (STAT5 pS726) in sensitive cell lines. Prolonged SEL120 treatment led to significant downregulation of CD34 and induction of lineage commitment markers. Transcriptomic analysis revealed that SEL120 regulated many genes involved in differentiation and apoptosis. We observed synergistic effects of SEL120 with standard of care cytotoxic drugs such as cytarabine. Treatment of AML cells with cytarabine spared many CD34+ cells, which could be effectively eradicated by subsequent treatment with SEL120. Many cell lines which were resistant to SEL120 treatment could be sensitized by concomitant treatment with BH3 mimetic agent ABT-199. Combination of both compounds resulted in potent induction of apoptosis in AML cells in vitro and in vivo. Treatment of mice bearing subcutaneously implanted human leukaemia cell lines resulted in significant tumour growth inhibition, whereas cotreatment with ABT-199 led to complete regressions at doses which were vey well tolerated by animals. Next we have selected patient derived primary AML cells using gene expression signatures identifying SEL120 -responder cell lines. In these cells SEL120 significantly reduced viability, induced apoptosis and lineage commitment. Further, the same cells were implanted into NOD scid gamma mice. Animals succumbed to AML, diagnosed by a significant presence of human CD45/CD34 positive leukaemia cells in a peripheral blood and splenomegaly. Stand-alone treatment with SEL120 resulted in the complete remission of AML cells in a peripheral blood and bone marrow, and reduced spleen weight, without symptoms of compound-related toxicity. These results validate SEL120 as a promising agent in the treatment of AML. Citation Format: Milena Mazan, Eliza Majewska, Michal Mikula, Katarzyna Wiklik, Michal Combik, Aniela Golas, Magdalena Masiejczyk, Elzbieta Fiedor, Anna Polak, Magdalena Cybulska, Aleksandra Grochowska, Michal Kopczynski, Urszula Kuklinska, Zuzanna Sandowska-Markiewicz, Malgorzata Statkiewicz, Agnieszka Paziewska, Michalina Dabrowska, Arkadiusz Bialas, Maciej Mikulski, Renata Windak, Jerzy Ostrowski, Przemyslaw Juszczynski, Krzysztof Brzozka, Tomasz Rzymski. SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1306." @default.
• W2953961312 created "2019-07-12" @default.
• W2953961312 creator A5000571424 @default.
• W2953961312 creator A5001498030 @default.
• W2953961312 creator A5003325753 @default.
• W2953961312 creator A5005000394 @default.
• W2953961312 creator A5007944267 @default.
• W2953961312 creator A5020059510 @default.
• W2953961312 creator A5025138388 @default.
• W2953961312 creator A5028489896 @default.
• W2953961312 creator A5030114028 @default.
• W2953961312 creator A5031726041 @default.
• W2953961312 creator A5035953024 @default.
• W2953961312 creator A5036099202 @default.
• W2953961312 creator A5045887904 @default.
• W2953961312 creator A5059410255 @default.
• W2953961312 creator A5060181038 @default.
• W2953961312 creator A5060648618 @default.
• W2953961312 creator A5061008099 @default.
• W2953961312 creator A5061408064 @default.
• W2953961312 creator A5077903818 @default.
• W2953961312 creator A5077983441 @default.
• W2953961312 creator A5081659477 @default.
• W2953961312 creator A5084411623 @default.
• W2953961312 creator A5088184588 @default.
• W2953961312 creator A5090057105 @default.
• W2953961312 date "2019-07-01" @default.
• W2953961312 modified "2023-10-17" @default.
• W2953961312 title "Abstract 1306: SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia" @default.
• W2953961312 doi "https://doi.org/10.1158/1538-7445.am2019-1306" @default.
• W2953961312 hasPublicationYear "2019" @default.
• W2953961312 type Work @default.
• W2953961312 sameAs 2953961312 @default.
• W2953961312 citedByCount "1" @default.
• W2953961312 countsByYear W29539613122021 @default.
• W2953961312 crossrefType "proceedings-article" @default.
• W2953961312 hasAuthorship W2953961312A5000571424 @default.
• W2953961312 hasAuthorship W2953961312A5001498030 @default.
• W2953961312 hasAuthorship W2953961312A5003325753 @default.
• W2953961312 hasAuthorship W2953961312A5005000394 @default.
• W2953961312 hasAuthorship W2953961312A5007944267 @default.
• W2953961312 hasAuthorship W2953961312A5020059510 @default.
• W2953961312 hasAuthorship W2953961312A5025138388 @default.
• W2953961312 hasAuthorship W2953961312A5028489896 @default.
• W2953961312 hasAuthorship W2953961312A5030114028 @default.
• W2953961312 hasAuthorship W2953961312A5031726041 @default.
• W2953961312 hasAuthorship W2953961312A5035953024 @default.
• W2953961312 hasAuthorship W2953961312A5036099202 @default.
• W2953961312 hasAuthorship W2953961312A5045887904 @default.
• W2953961312 hasAuthorship W2953961312A5059410255 @default.
• W2953961312 hasAuthorship W2953961312A5060181038 @default.
• W2953961312 hasAuthorship W2953961312A5060648618 @default.
• W2953961312 hasAuthorship W2953961312A5061008099 @default.
• W2953961312 hasAuthorship W2953961312A5061408064 @default.
• W2953961312 hasAuthorship W2953961312A5077903818 @default.
• W2953961312 hasAuthorship W2953961312A5077983441 @default.
• W2953961312 hasAuthorship W2953961312A5081659477 @default.
• W2953961312 hasAuthorship W2953961312A5084411623 @default.
• W2953961312 hasAuthorship W2953961312A5088184588 @default.
• W2953961312 hasAuthorship W2953961312A5090057105 @default.
• W2953961312 hasConcept C10205521 @default.
• W2953961312 hasConcept C11960822 @default.
• W2953961312 hasConcept C150903083 @default.
• W2953961312 hasConcept C203014093 @default.
• W2953961312 hasConcept C207001950 @default.
• W2953961312 hasConcept C2776414213 @default.
• W2953961312 hasConcept C2778041864 @default.
• W2953961312 hasConcept C2778461978 @default.
• W2953961312 hasConcept C2778729363 @default.
• W2953961312 hasConcept C2779282312 @default.
• W2953961312 hasConcept C2779391668 @default.
• W2953961312 hasConcept C28328180 @default.
• W2953961312 hasConcept C502942594 @default.
• W2953961312 hasConcept C54355233 @default.
• W2953961312 hasConcept C71924100 @default.
• W2953961312 hasConcept C81885089 @default.
• W2953961312 hasConcept C86803240 @default.
• W2953961312 hasConcept C95444343 @default.
• W2953961312 hasConcept C98175054 @default.
• W2953961312 hasConcept C98274493 @default.
• W2953961312 hasConceptScore W2953961312C10205521 @default.
• W2953961312 hasConceptScore W2953961312C11960822 @default.
• W2953961312 hasConceptScore W2953961312C150903083 @default.
• W2953961312 hasConceptScore W2953961312C203014093 @default.
• W2953961312 hasConceptScore W2953961312C207001950 @default.
• W2953961312 hasConceptScore W2953961312C2776414213 @default.
• W2953961312 hasConceptScore W2953961312C2778041864 @default.
• W2953961312 hasConceptScore W2953961312C2778461978 @default.
• W2953961312 hasConceptScore W2953961312C2778729363 @default.
• W2953961312 hasConceptScore W2953961312C2779282312 @default.
• W2953961312 hasConceptScore W2953961312C2779391668 @default.
• W2953961312 hasConceptScore W2953961312C28328180 @default.
• W2953961312 hasConceptScore W2953961312C502942594 @default.
• W2953961312 hasConceptScore W2953961312C54355233 @default.
• W2953961312 hasConceptScore W2953961312C71924100 @default.
• W2953961312 hasConceptScore W2953961312C81885089 @default.
• W2953961312 hasConceptScore W2953961312C86803240 @default.
• W2953961312 hasConceptScore W2953961312C95444343 @default.
• W2953961312 hasConceptScore W2953961312C98175054 @default.
• W2953961312 hasConceptScore W2953961312C98274493 @default.

• next